Neogenomics Stock Today
| NEO Stock | USD 12.40 0.02 0.16% |
PerformanceGood
| Odds Of DistressSmall
|
NeoGenomics is selling at 12.40 as of the 29th of January 2026; that is 0.16 percent increase since the beginning of the trading day. The stock's open price was 12.38. NeoGenomics has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 31st of October 2025 and ending today, the 29th of January 2026. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 2nd of November 1999 | Category Healthcare | Classification Health Care |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 129.39 M outstanding shares of which 8.09 M shares are now shorted by investors with about 4.41 days to cover. More on NeoGenomics
Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
NeoGenomics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Anthony Zook | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Quadient SAS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Providers & Services, Health Care Equipment & Services, Health Care, ARCA Biotechnology, SP Small-Cap 600, NASDAQ Composite Total, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Providers & Services, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNeoGenomics utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into NeoGenomics' leverage profile, showing how much of NeoGenomics' resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NeoGenomics (NEO) is traded on NASDAQ Exchange in USA and employs 2,200 people. NeoGenomics is listed under Health Care Providers & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 1.6 B. NeoGenomics runs under Health Care Providers & Services sector within Health Care industry. The entity has 129.39 M outstanding shares of which 8.09 M shares are now shorted by investors with about 4.41 days to cover.
NeoGenomics has about 465.95 M in cash with 7.02 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7.
Check NeoGenomics Probability Of Bankruptcy
Ownership AllocationThe majority of NeoGenomics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NeoGenomics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NeoGenomics. Please pay attention to any change in the institutional holdings of NeoGenomics as this could imply that something significant has changed or is about to change at the company.
Check NeoGenomics Ownership Details
NeoGenomics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 3.2 M | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.5 M | |
| Gw&k Investment Management, Llc | 2025-06-30 | 2.5 M | |
| Segall Bryant & Hamill | 2025-06-30 | 2.4 M | |
| Deerfield Management Co | 2025-06-30 | 2.1 M | |
| Hhg Plc | 2025-06-30 | 2 M | |
| Jennison Associates Llc | 2025-06-30 | 1.7 M | |
| Bank Of America Corp | 2025-06-30 | 1.5 M | |
| Goldman Sachs Group Inc | 2025-06-30 | 1.5 M | |
| Blackrock Inc | 2025-06-30 | 19.4 M | |
| Vanguard Group Inc | 2025-06-30 | 14.1 M |
NeoGenomics Historical Income Statement
NeoGenomics Stock Against Markets
NeoGenomics Corporate Management
| Nathan MD | Vice Services | Profile | |
| George Cardoza | Pres Operations | Profile | |
| Gary Passman | Chief Officer | Profile | |
| Alicia Olivo | General Development | Profile | |
| Andrew Lukowiak | Chief Officer | Profile | |
| Cynthia Dieter | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.